Biodexa's FAP trial two-thirds enrolled, timeline moves up; GIST pre-IND meeting set for December
Biodexa said its Serenta trial could hit futility analysis in early 2027, sooner than planned, while MTX240 heads toward a December pre-IND meeting with the FDA.
SEC filing (6)